Palo Alto, California, January 19, 2017 – Altamont Capital Partners (“Altamont”), the San Francisco Bay area‐based private equity firm with over $2 billion under management, announced today that Michael A. Griffith has joined the firm as an Operating Partner. Mr. Griffith will partner with the Altamont team to acquire and build market leading companies in the pharmaceutical services sector.
Mr. Griffith is a proven executive with over 20 years of experience running businesses that provide agency regulated outsourced services to pharmaceutical clients. Most recently he was President of the Commercial Division of inVentiv Health, a leading global provider of biopharmaceutical outsourcing services across the continuum of research and commercialization of drugs. Prior to inVentiv, Michael was CEO at Laureate Biopharma, a contract development and manufacturing company specializing in protein therapeutics; Founder and CEO of Aptuit, a global contract drug development company; and Chairman and CEO of ChiRex, a global contract development and manufacturing business. Michael has served on numerous public company boards including the board of Repligen Corporation. Mr. Griffith started his career at Credit Suisse First Boston and Bankers Trust Company in New York.
“We are very excited to partner with Michael to build a leading platform in the pharmaceutical services space,” said Altamont Managing Director Casey Lynch. “Michael’s broad base of relevant experience with multiple successful platform companies across a range of outsourced services and his deep network of relationships with biopharmaceutical companies positions Altamont to actively pursue investment opportunities across the pharmaceutical value chain.”
Mr. Griffith added: “I am delighted to partner with the Altamont team to pursue new investment opportunities. Over the course of my work with Altamont to date, I have come to appreciate the firm’s thoughtful approach and willingness to dig into complex situations, deep respect for the managers of their portfolio companies, and the wealth of resources Altamont brings to value creation. We believe there are a number of opportunities to invest capital in this sector which will benefit from their unique approach.”
“Altamont’s partnership with Michael demonstrates our interest in investing capital in this growing segment of healthcare,” added Melissa Francis, Principal at Altamont. “We believe the combination of his expertise in the industry and Altamont’s expertise in healthcare investing, with a particular focus on corporate carve-out transactions and transitioning family- and founder-owned businesses, make us a unique potential partner for businesses in the space.”